Top Qs
Timeline
Chat
Perspective
Compass Pathways
British psychedelic medicine company From Wikipedia, the free encyclopedia
Remove ads
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines.[1][2][3] Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression.[1][2][4] This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA).[1] It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).[2]
Compass Pathways is the largest company in the psychedelic medicine industry[5] and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ.[1] It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species.[1][5] In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder (PTSD) New Drug Application (NDA), Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.[6]
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.[7][8][9][10][11][12] Wallach's lab is said to have sought patents for over 200 novel compounds as of May 2024.[11]
Compass Pathways switched from being a nonprofit organization to a for-profit company in 2016.[10] The pharmaceutical company has been backed and funded by a number of tech entrepreneurs such as Peter Thiel.[5]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads